C. June
Oncology · 2002–2022
A researcher in the Science corpus: 39 papers; trusts 17 researchers and is trusted by 18 researchers here, as inferred from the citation graph.
Subfields
- Oncology — 364 citations into it; #102 of 1,698 by trust here, #29 by citations
- Immunology — 324 citations into it; #1,195 of 2,160 by trust here, #125 by citations
- Molecular Biology — 188 citations into it
- Genetics — 131 citations into it; #1,479 of 6,854 by trust here, #156 by citations
- Radiology, Nuclear Medicine and Imaging — 23 citations into it
Whom C. June trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
- R. Morgan
- D. Porter
- Kole T. Roybal
- J. Kochenderfer
- Jie Yang
- Leonardo Morsut
- M. Dudley
- Wendell A. Lim
- S. Rosenberg
- S. Maude
Who trusts C. June overall
Papers from C. June's perspective
Ordered by how strongly the researchers C. June trusts endorse each paper. Same corpus, a different order for every researcher.
- Cancer regression and neurologic toxicity following anti-MAGE-A3 TCR gene therapy (Journal of immunotherapy)
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia (Science Translational Medicine)
- A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer (Clinical Cancer Research)
- T cell exhaustion (Nature Immunology)
- Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate… (Journal of Clinical Oncology)
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia (Science Translational Medicine)
- Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells (Science Translational Medicine)
- Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. (Science)
- Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with… (Blood)
- The CD28 signaling pathway regulates glucose metabolism. (Immunity)
Their papers
- Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases (2008) — 1,058 citations
- The Principles of Engineering Immune Cells to Treat Cancer (2017) — 970 citations
- Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition (2016) — 832 citations
- NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma (2015) — 823 citations
- Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. (2016) — 1,075 citations
- Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased anti-leukemic efficacy in vivo (2009) — 1,165 citations
- Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. (2013) — 1,129 citations
- Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T-cells (2012) — 649 citations
- CAR T cells produced in vivo to treat cardiac injury (2022) — 1,136 citations
- Decade-long leukaemia remissions with persistence of CD4+ CAR T cells (2022) — 759 citations
- Human chimeric antigen receptor macrophages for cancer immunotherapy (2020) — 1,262 citations
- Cytokine Storm (2020) — 1,207 citations
- Cytokine release syndrome in severe COVID-19 (2020) — 1,792 citations
- CRISPR-engineered T cells in patients with refractory cancer (2020) — 1,260 citations
- Delivery technologies for cancer immunotherapy (2019) — 2,125 citations
- Targeting Cardiac Fibrosis with Engineered T cells (2019) — 650 citations
- CAR T cell immunotherapy for human cancer (2018) — 2,700 citations
- Chimeric Antigen Receptor Therapy (2018) — 1,841 citations
- Activity of Mesothelin-specific Chimeric Antigen Receptor T cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial (2018) — 427 citations
- Disruption of TET2 Promotes the Therapeutic Efficacy of CD19-targeted T-cells (2018) — 771 citations